John Fry

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal et al. · Blood · 2011 · 341 citations · Full text

Medicine, Hematology, Oncology +15

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Fabien Zoulim, Oliver Lenz, Joris Vandenbossche et al. · Gastroenterology · 2020 · 116 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans

Kashyap Patel, Carl M. J. Kirkpatrick, Keith Nieforth et al. · Journal of Antimicrobial Chemotherapy · 2018 · 42 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

Abbie Oey, Matthew W. McClure, Julian Symons et al. · PLoS ONE · 2023 · 30 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, Philippe Moreau, Andrzej Jakubowiak et al. · Blood · 2010 · 28 citations

Medicine, Hematology, Oncology +14